Sen.
Rick Scott (R-Fla.) warned that China’s latest regulatory moves could increase risks for U.S. companies and pharmaceutical supply chains, urging policymakers to reduce America’s dependence on Beijing for critical medicines.
Scott Targets China’s Drug Rules On Tuesday, in a post on X, Scott criticized China’s government over new rules that he said could pressure U.S. companies that follow American laws or attempt to shift manufacturing away from China.
He said, "China’s government passed new rules that harm U.S. companies who comply with U.S law or try to move production out of China." In a video shared alongside the post, Scott questioned China’s intentions, saying, "What’s the odds that the government of Communist China has some new decree that’s good for us?" He said the new measures would restrict U.S. regulators’ ability to access information about medicines produced in China.
"They say the FDA can't know about drugs that are made in China.
